The method described here allows the efficient generation of a series of different human-like glycoforms at large homogeneity of virtually any antibody within one week after cDNA delivery to plants. This accelerates follow up functional studies and thus may contribute to study the biological role of N-glycan residues on Fcs and maximizing the clinical efficacy of therapeutic antibodies.
No takes yet. Share an insight, caveat, or question.
Castilho et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: